Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | PLG | P00747 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | CTSG | P08311 | 1/20 | 0.35 |
| ▸ | CMA1 | P23946 | 1/20 | 0.35 |
| ▸ | CTRC | Q99895 | 1/20 | 0.35 |
| ▸ | MC4R | P32245 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28113285 | 0.82 | LMNA (0.40) | CYP19A1GAAALDH1A1POLBCYP1A2 | |
| SCHEMBL28855639 | 0.82 | SLC6A3 (0.42) | SIGMAR1GAAL3MBTL1CYP1A2CYP2D6 | |
| SCHEMBL28193189 | 0.78 | SIGMAR1 (0.44) | SIGMAR1KDM4ECMA1GAAALDH1A1 | |
| SCHEMBL28137179 | 0.78 | KDM4E (0.45) | KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL32688445 | 0.77 | HCRTR1 (0.33) | SIGMAR1KDM4ECMA1GAAALDH1A1 | |
| SCHEMBL27450821 | 0.76 | ALDH1A1 (0.35) | ALDH1A1DRD4 | |
| SCHEMBL28238610 | 0.73 | HTT (0.42) | KDM4ETSHRALDH1A1L3MBTL1DRD4 | |
| SCHEMBL28230095 | 0.73 | TSHR (0.37) | KDM4ETSHRNPSR1GAAALDH1A1 | |
| SCHEMBL7057369 | 0.71 | ALDH1A1 (0.42) | KDM4ENPSR1GAAALDH1A1POLB | |
| SCHEMBL23290132 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12485121-B2 | Antiviral agents for the treatment and prevention of HIV infection | PHARMASYNTEZ, JOINT STOCK COMPANY (RU) | 2025-12-02 | — | — | US | disclosed |
| US-20230120294-A1 | ANTIVIRAL AGENTS FOR THE TREATMENT AND PREVENTION OF HIV INFECTION | PHARMASYNTEZ, JOINT STOCK COMPANY (RU) | 2023-04-20 | — | — | US | disclosed |
| CN-115279757-A | Pyrimidine bicyclic compounds as antiviral agents for the treatment and prevention of HIV infection | 法玛西泰股份公司 | 2022-11-01 | — | — | CN | disclosed |
| EP-3455205-A1 | PEPTIDOMIMETICS FOR THE TREATMENT OF NOROVIRUS INFECTION | Emory University (US) | 2019-03-20 | — | — | EP | disclosed |
| WO-2017197377-A1 | PEPTIDOMIMETICS FOR THE TREATMENT OF NOROVIRUS INFECTION | EMORY UNIVERSITY (US) | 2017-11-16 | — | — | WO | disclosed |
| WO-2017075590-A2 | PROCESSES FOR PREPARING 2-DIHALO RIBOLACTONES | COCRYSTAL PHARMA, INC. (US) | 2017-05-04 | — | — | WO | disclosed |
| EP-3134423-A1 | 2' -DISUBSTITUTED NUCLEOSIDE ANALOGS FOR TREATMENT OF THE FLAVIVIRIDAE FAMILY OF VIRUSES AND CANCER | Cocrystal Pharma, Inc. (US) | 2017-03-01 | — | — | EP | disclosed |
| WO-2015164812-A1 | 2' -DISUBSTITUTED NUCLEOSIDE ANALOGS FOR TREATMENT OF THE FLAVIVIRIDAE FAMILY OF VIRUSES AND CANCER | COCRYSTAL PHARMA, INC. (US) | 2015-10-29 | — | — | WO | disclosed |
| EP-1461041-A4 | PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES | PHARMASSET LTD (BB) | 2006-03-29 | — | — | EP | disclosed |
| EP-1461041-A2 | PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES | Pharmasset Ltd. (BB) | 2004-09-29 | — | — | EP | disclosed |
| EP-1373288-A1 | PROCESS FOR THE PREPARATION OF 2'-HALO-BETA-L-ARABINOFURANOSYL NUCLEOSIDES | Triangle Pharmaceuticals Inc. (US) | 2004-01-02 | — | — | EP | disclosed |
| WO-2003051298-A2 | PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES | PHARMASSET LTD. (BB) | 2003-06-26 | — | — | WO | disclosed |
| WO-2002079213-A1 | PROCESS FOR THE PREPARATION OF 2'-HALO-$G(B)-L-ARABINOFURANOSYL NUCLEOSIDES | TRIANGLE PHARMACEUTICALS, INC. (US) | 2002-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12485121-B2 | Antiviral agents for the treatment and prevention of HIV infection | TYMP, TYMS, UMPS | SIGMAR1 3799/4885CYP19A1 4187/4885KDM4E 2715/4885 |
| US-20230120294-A1 | ANTIVIRAL AGENTS FOR THE TREATMENT AND PREVENTION OF HIV INFECTION | TYMP, TYMS, UMPS | SIGMAR1 3799/4885CYP19A1 4187/4885KDM4E 2715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.